For laboratory and research use only. Not for human consumption.
Comparison

NA-Selank Amidate vs Orexin A

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

NA-Selank Amidate

Also: N-Acetyl Selank Amidate, NA-Selank

Clinical Trials

NA-Selank Amidate is a chemically stabilized version of Selank, a Russian anxiolytic peptide derived from the immune fragment tuftsin. The acetyl group on one end and the amide on the other are there to slow enzymatic breakdown, which is a real and sensible modification. What has not been established is whether that translates into a meaningfully better result than plain Selank in humans.

CognitiveHuman Trials
Orexin A

Also: Hypocretin-1, Hcrt-1

Clinical Trials

Orexin A (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. People with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. Orexin A itself is not an approved drug, but a few small German studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. Interesting science, very early stage.

CognitiveHuman Trials

Key Comparison Insights

  • Both peptides belong to the Cognitive category, suggesting similar primary applications.

Detailed Comparison

AttributeNA-Selank AmidateOrexin A
CategoryCognitiveCognitive
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionSelank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide fragment. Its reported mechanism has two strands. The first is modulation of GABAergic signalling, which is the basis of its anxiolytic reputation, achieved without the sedation, tolerance or dependence associated with benzodiazepines. The second is an effect on the balance of monoamines and on BDNF expression, which is where the cognitive and mood claims come from. It also retains some of tuftsin's immunomodulatory activity, including effects on interleukin expression. The N-acetylation and C-terminal amidation in this version block the exopeptidases that would otherwise clip the peptide quickly, extending how long it survives after administration. That is a pharmacokinetic change, not a new mechanism.Orexin A activates both orexin receptors (OX1R and OX2R) with high affinity. Those receptors sit on brainstem and hypothalamic arousal centers (the histamine, noradrenaline, dopamine and acetylcholine systems), so orexin acts like a stabilizer that keeps the brain locked in the wake state and stops it slipping into REM sleep at the wrong time. Losing it causes narcolepsy: orexin knockout mice and dogs with a broken OX2R gene both develop narcolepsy, and giving orexin A into the brain of narcoleptic mice suppressed cataplexy. Orexin also drives appetite and raises sympathetic nerve activity. A mouse study found orexin A crosses the blood-brain barrier fairly well, and the nasal route is used in humans to deliver more of it to the brain.
Common Dosing
250-500 mcg daily
Once or twice daily
435 nmol (about 1.5 mg) intranasal
Single dose in studies
AdministrationIntranasal is the standard route. Subcutaneous is reported but less common.Intranasal spray
Typical DurationCommunity protocols commonly report 2-4 weeks, though Selank's clinical use does not indicate a dependence risk requiring cyclingSingle doses only in published human studies
Best Time to TakeMorning or split across the dayMorning
Possible Side Effects
May vary by individual
  • Generally reported as well tolerated
  • Nasal irritation or dryness with intranasal use
  • Mild fatigue or flat affect at higher doses
  • Headache
  • No dependence or withdrawal syndrome reported, unlike benzodiazepines
  • +1 more
  • Long-term human safety is unknown: published studies used single doses
  • Increased sympathetic (fight-or-flight) nerve activity seen in healthy men
  • Possible sleep disruption if taken late, since it promotes wakefulness
  • Increased appetite in animal studies
  • Theoretical blood pressure concerns with repeated use
  • +1 more
Research SummarySelank itself has a real research base, almost all of it Russian, including clinical work in generalised anxiety disorder where it performed comparably to benzodiazepines without the sedation and withdrawal profile, plus animal work supporting the BDNF and monoamine effects. That literature is genuine but it is largely published in Russian journals, has not been replicated in large Western trials, and has not been through FDA or EMA assessment. The amidate variant specifically has essentially no independent published pharmacology. The stability argument is chemically sound and is the same modification used across many research peptides, but nobody has published a human comparison showing it outperforms standard Selank at equivalent doses. Treat the parent compound's evidence as real but geographically narrow, and the variant's advantage as plausible rather than demonstrated.The human data comes from a handful of small, placebo-controlled crossover studies, mostly from one group in Kiel, Germany. In 2008, intranasal orexin A improved smell detection thresholds in 7 narcolepsy patients. In 2011, a single 435 nmol nasal dose before bed in 8 patients did not change nighttime wakefulness but reduced REM sleep and wake-to-REM transitions. In 2014, the same dose given in the morning to 14 patients reduced wake-REM transitions and improved divided attention (fewer errors). In 2022, 500 nmol in 10 healthy men acutely raised sympathetic nerve activity to blood vessels, without changing blood pressure or heart rate. In sleep-deprived monkeys, nasal orexin A reversed some of the drop in memory performance (Deadwyler, 2007). That is the whole human record: single doses, tiny groups, short-term outcomes. The real clinical action has moved to small-molecule drugs that mimic orexin at OX2R. Takeda's oveporexton (brand name Orzeyful) was FDA-approved on August 5, 2026 for narcolepsy type 1, which validates the target but is not the same thing as using the peptide.

Frequently Asked Questions: NA-Selank Amidate vs Orexin A

What is the difference between NA-Selank Amidate and Orexin A?

NA-Selank Amidate is a cognitive peptide that na-selank amidate is a chemically stabilized version of selank, a russian anxiolytic peptide derived from the immune fragment tuftsin. the acetyl group on one end and the amide on the other are there to slow enzymatic breakdown, which is a real and sensible modification. what has not been established is whether that translates into a meaningfully better result than plain selank in humans. Orexin A is a cognitive peptide that orexin a (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. people with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. orexin a itself is not an approved drug, but a few small german studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. interesting science, very early stage. The main differences lie in their mechanisms of action and clinical applications.

Which is better, NA-Selank Amidate or Orexin A?

Neither is universally "better" - the choice depends on your specific goals. NA-Selank Amidate is typically used for cognitive purposes, while Orexin A is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can NA-Selank Amidate and Orexin A be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using NA-Selank Amidate and Orexin A together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles